Botulinum neurotoxin A for benign prostatic hyperplasia

Oeconomou, Athanassios; Madersbacher, H.

doi:10.1097/mou.0b013e328333ac01

Cited by 14 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, abundance of adrenergic and muscarinic receptors and nerve fibers suggests that the autonomic nervous system may play a role in the growth and secretory function of the gland [74]. It has been also found that a subtype of muscarinic receptors is present in BPH and was the predominant subtype there.…”

Section: Discussionmentioning

confidence: 97%

“…Sixty patients received add-on intraprostatic BoNT-A or continued medical therapy The initial results of a two-stage, multicenter, double-blind, randomized, phase II clinical trial of two doses of intraprostatic injection of BoNT-A, funded by NIH, have been reported [74][75][76]. One hundred and thirty-four patients underwent injection of 100 or 300 UI of BoNT-A.…”

Section: Bont-a Effects In Human Prostatementioning

confidence: 99%

See 1 more Smart Citation

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Brisinda

Vanella²,

Marniga³

et al. 2011

CMC

View full text Add to dashboard Cite

Botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several disorders; the use of this agent has extended to a plethora of conditions including focal dystonia, spasticity, inappropriate contraction in most gastrointestinal sphincters, eye movement disorders, hyperhidrosis, genitourinary disorders and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of pain, and for the management of tension or migraine headaches and myofascial pain syndrome. Benign prostatic hyperplasia (BPH) is a common condition in ageing men; the goal of therapy is to reduce the lower urinary tract symptoms (LUTS) associated with BPH and to improve the quality of life. However, medical treatment, including drugs that relax smooth muscle within the prostate and drugs that shrink the gland are not totally effective or without complications. The standard surgical treatment for BPH is progressively changing to minimally invasive therapies, but none of them has provided clear results. The use of BoNT-A to inhibit the autonomic efferent effects on prostate growth and contraction, and inhibit the abnormal afferent effects on prostate sensation, might be an alternative treatment for BPH. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease; systemic pharmacologic effects are rare, permanent destruction of tissue does not occur, and graded degrees of relaxation may be achieved by varying the dose injected. In this paper, clinical experience over the last years with BoNT in BPH impaired patients will be illustrated.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Bont-a Effects In Human Prostatementioning

confidence: 99%

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Brisinda

Vanella²,

Marniga³

et al. 2011

CMC

View full text Add to dashboard Cite

show abstract

“…Botulinum neurotoxin (BoNT) that block at the injection site the release of neurotransmitters, for example, acetylcholine and norepinephrine, from pre‐synaptic nerves, has been demonstrated to affect sympathetic activity in urethral smooth muscle . Injection of BoNT at the level of bladder neck, urethra, and prostate is a novel emerging treatment for LUTS caused by BPH or by voiding dysfunctions characterized by non‐relaxing proximal urethra/bladder neck, however, only a pilot study including eight patients followed‐up for 32 weeks has been published on its use to treat PBND …”

Section: Introductionmentioning

confidence: 99%

OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder‐neck dysfunction: Objective and patient‐reported outcomes

Sacco

Tienforti²,

Bientinesi

et al. 2013

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…However, findings from clinical trials have been falling short of expectations. [57][58][59][60][61] Clinical results Clinical results of trials investigating BoNT-A treatment in BPH-associated LUTS are heterogeneous and only partially confirm the effects of BoNT-A observed in experimental studies. The clinical efficacy and safety of different dose ranges of BoNT-A (100 U-300 U) have Nature Reviews | Urology been assessed in several non-placebo-controlled clinical trials.…”

Section: Mechanism Of Actionmentioning

confidence: 89%

New intraprostatic injectables and prostatic urethral lift for male LUTS

2015

View full text Add to dashboard Cite

Treatment modalities for male lower urinary tract symptoms (LUTS) comprise a broad spectrum of medical and surgical options. Interest is growing in minimally invasive treatment options, which should ideally be performed in an outpatient setting and have a short recovery time, durable efficacy and a good safety profile. The preservation of all aspects of sexual function, including antegrade ejaculation, seems to be increasingly important for patients. Initial experimental data on new minimally invasive procedures-such as the intraprostatic injection of novel agents including botulinum neurotoxin A (BoNT-A), NX-1207 and PRX302-were promising, but clinical trials have not confirmed the findings. Trials of the mechanical prostatic urethral lift device-Urolift(®) (Neotract, Inc., USA)-have been positive, but further long-term results are needed to confirm its beneficial effects.

show abstract

Botulinum neurotoxin A for benign prostatic hyperplasia

Cited by 14 publications

References 42 publications

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder‐neck dysfunction: Objective and patient‐reported outcomes

New intraprostatic injectables and prostatic urethral lift for male LUTS

Contact Info

Product

Resources

About